Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

Cited In for PubMed (Select 19605829)

1.

Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.

Saykin AJ, Shen L, Yao X, Kim S, Nho K, Risacher SL, Ramanan VK, Foroud TM, Faber KM, Sarwar N, Munsie LM, Hu X, Soares HD, Potkin SG, Thompson PM, Kauwe JS, Kaddurah-Daouk R, Green RC, Toga AW, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):792-814. doi: 10.1016/j.jalz.2015.05.009. Review.

2.

Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.

Roberts JS, Dunn LB, Rabinovici GD.

Neurodegener Dis Manag. 2013;3(3):219-229.

3.

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.

Harkins K, Sankar P, Sperling R, Grill JD, Green RC, Johnson KA, Healy M, Karlawish J.

Alzheimers Res Ther. 2015 May 12;7(1):26. doi: 10.1186/s13195-015-0112-7. eCollection 2015.

4.

The rise of multiple imputation: a review of the reporting and implementation of the method in medical research.

Hayati Rezvan P, Lee KJ, Simpson JA.

BMC Med Res Methodol. 2015 Apr 7;15:30. doi: 10.1186/s12874-015-0022-1.

5.

Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.

Kim SY, Karlawish J, Berkman BE.

Neurology. 2015 Apr 7;84(14):1488-94. doi: 10.1212/WNL.0000000000001451. Epub 2015 Mar 11. Review.

PMID:
25762713
6.

Associations between self-referral and health behavior responses to genetic risk information.

Christensen KD, Roberts JS, Zikmund-Fisher BJ, Kardia SL, McBride CM, Linnenbringer E, Green RC; REVEAL Study Group.

Genome Med. 2015 Jan 31;7(1):10. doi: 10.1186/s13073-014-0124-0. eCollection 2015.

7.

Factors affecting recall of different types of personal genetic information about Alzheimer's disease risk: the REVEAL study.

Besser AG, Sanderson SC, Roberts JS, Chen CA, Christensen KD, Lautenbach DM, Cupples LA, Green RC.

Public Health Genomics. 2015;18(2):78-86. doi: 10.1159/000368888. Epub 2015 Jan 24.

PMID:
25634646
8.

Information Avoidance Tendencies, Threat Management Resources, and Interest in Genetic Sequencing Feedback.

Taber JM, Klein WM, Ferrer RA, Lewis KL, Harris PR, Shepperd JA, Biesecker LG.

Ann Behav Med. 2015 Aug;49(4):616-21. doi: 10.1007/s12160-014-9679-7.

PMID:
25582989
9.

Integrating big data and actionable health coaching to optimize wellness.

Hood L, Lovejoy JC, Price ND.

BMC Med. 2015 Jan 9;13:4. doi: 10.1186/s12916-014-0238-7.

10.

The fiduciary relationship model for managing clinical genomic "incidental" findings.

Lázaro-Muñoz G.

J Law Med Ethics. 2014 Winter;42(4):576-89. doi: 10.1111/jlme.12177.

11.

Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients.

Li JH, Joy SV, Haga SB, Orlando LA, Kraus WE, Ginsburg GS, Voora D.

J Pers Med. 2014 Mar 27;4(2):147-62. doi: 10.3390/jpm4020147.

12.

A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease.

Green RC, Christensen KD, Cupples LA, Relkin NR, Whitehouse PJ, Royal CD, Obisesan TO, Cook-Deegan R, Linnenbringer E, Butson MB, Fasaye G, Levinson E, Roberts JS; REVEAL Study Group.

Alzheimers Dement. 2014 Dec 9. pii: S1552-5260(14)02870-2. doi: 10.1016/j.jalz.2014.10.014. [Epub ahead of print]

PMID:
25499536
13.

Before it is too late: professional responsibilities in late-onset Alzheimer's research and pre-symptomatic prediction.

Schicktanz S, Schweda M, Ballenger JF, Fox PJ, Halpern J, Kramer JH, Micco G, Post SG, Thompson C, Knight RT, Jagust WJ.

Front Hum Neurosci. 2014 Nov 20;8:921. doi: 10.3389/fnhum.2014.00921. eCollection 2014.

14.

Communicating results in post-Belmont era biomonitoring studies: lessons from genetics and neuroimaging research.

Morello-Frosch R, Varshavsky J, Liboiron M, Brown P, Brody JG.

Environ Res. 2015 Jan;136:363-72. doi: 10.1016/j.envres.2014.10.001. Epub 2014 Nov 25. Review.

PMID:
25460657
15.

Should we disclose amyloid imaging results to cognitively normal individuals?

Grill JD, Johnson DK, Burns JM.

Neurodegener Dis Manag. 2013 Feb;3(1):43-51.

16.
17.

Public perceptions of presymptomatic testing for Alzheimer disease.

Caselli RJ, Langbaum J, Marchant GE, Lindor RA, Hunt KS, Henslin BR, Dueck AC, Robert JS.

Mayo Clin Proc. 2014 Oct;89(10):1389-96. doi: 10.1016/j.mayocp.2014.05.016. Epub 2014 Aug 26.

PMID:
25171823
18.

Return of individual genetic results in a high-risk sample: enthusiasm and positive behavioral change.

Hartz SM, Olfson E, Culverhouse R, Cavazos-Rehg P, Chen LS, DuBois J, Fisher S, Kaphingst K, Kaufman D, Plunk A, Ramnarine S, Solomon S, Saccone NL, Bierut LJ.

Genet Med. 2015 May;17(5):374-9. doi: 10.1038/gim.2014.110. Epub 2014 Aug 28.

PMID:
25166427
19.

Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study: rationale and design for a randomized controlled trial evaluating rheumatoid arthritis risk education to first-degree relatives.

Sparks JA, Iversen MD, Miller Kroouze R, Mahmoud TG, Triedman NA, Kalia SS, Atkinson ML, Lu B, Deane KD, Costenbader KH, Green RC, Karlson EW.

Contemp Clin Trials. 2014 Sep;39(1):145-57. doi: 10.1016/j.cct.2014.08.007. Epub 2014 Aug 20.

PMID:
25151341
20.

The potential applications of Apolipoprotein E in personalized medicine.

Villeneuve S, Brisson D, Marchant NL, Gaudet D.

Front Aging Neurosci. 2014 Jul 8;6:154. doi: 10.3389/fnagi.2014.00154. eCollection 2014. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk